Romani Eleonora, Zullino Sara, Speciale Anna R, Villa Paola M, Bonaldo Veronica, Parisi Francesca, Lubrano Chiara, Petraglia Felice, Cetin Irene, Mecacci Federico
Obstetrics and Gynaecology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.
High Risk Pregnancy Unit, Department for Women and Health, Careggi University Hospital, 50134 Florence, Italy.
Nutrients. 2025 Aug 19;17(16):2670. doi: 10.3390/nu17162670.
: To assess the impact of intravenous ferric carboxymaltose (FCM) on fetal and maternal adverse effects in pregnant women diagnosed with iron deficiency anemia (IDA). : This is a multicenter retrospective study on 472 pregnant women diagnosed with moderate to severe IDA undergoing treatment with FCM between 2019 and 2025 at Careggi University Hospital (Florence) and Vittore Buzzi Children Hospital (Milan). Fetal wellbeing was assessed using computerized cardiotocography (cCTG) or ultrasound, based on gestational age at treatment. Maternal side effects were evaluated through clinical evaluation. : cCTG was performed in 377/472 patients (80%), with a mean short-term variability of 10.2 ms. Normal cCTG criteria were met in 98.4% of cases; six patients exhibited transient reduced variability, which resolved following intrauterine resuscitation. Ultrasound assessment was performed in 95 patients (20%), revealing no fetal heart rate abnormalities. Maternal side effects occurred in seven patients (1.4%). Hemoglobin concentrations increased by a median of 1.4 g/dL after five weeks, reaching up to 2.8 g/dL in women with a baseline Hb < 8 g/dL. : Our findings support the potential safety and efficacy of intravenous FCM for the treatment of IDA during pregnancy, demonstrating low rates of maternal side effects and no adverse fetal heart rate patterns. However, prospective studies are necessary to confirm these results.
评估静脉注射羧基麦芽糖铁（FCM）对诊断为缺铁性贫血（IDA）的孕妇胎儿及母体不良反应的影响。
这是一项多中心回顾性研究，研究对象为2019年至2025年期间在卡雷吉大学医院（佛罗伦萨）和维托雷·布齐儿童医院（米兰）接受FCM治疗的472例诊断为中度至重度IDA的孕妇。根据治疗时的孕周，使用计算机化心动图（cCTG）或超声评估胎儿健康状况。通过临床评估来评估母体副作用。
377/472例患者（80%）进行了cCTG检查，平均短期变异性为10.2毫秒。98.4%的病例符合正常cCTG标准；6例患者出现短暂变异性降低，经宫内复苏后恢复。95例患者（20%）进行了超声评估，未发现胎儿心率异常。7例患者（1.4%）出现母体副作用。五周后血红蛋白浓度中位数增加1.4 g/dL，基线血红蛋白<8 g/dL的女性血红蛋白浓度增加高达2.8 g/dL。
我们的研究结果支持静脉注射FCM治疗孕期IDA的潜在安全性和有效性，表明母体副作用发生率低，且未出现不良胎儿心率模式。然而，需要进行前瞻性研究来证实这些结果。
